Evidence map›Paper›PMID 40171013›Full record

ArticleClinical case reports2025

Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.

Jose Antonio Sánchez Salas, Maria Jose Moreno Belmonte, Andrea Poveda García, Estela Ruiz Ruiz, Eva Soler Espejo, Valentin Cabanas Perianes, Ana María García Hernandez

Abstract read
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jose Antonio Sánchez SalasDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.ORCID https://orcid.org/0009-0001-0140-044X
Maria Jose Moreno BelmonteDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Andrea Poveda GarcíaDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Estela Ruiz RuizDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Eva Soler EspejoDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.
Valentin Cabanas PerianesDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.ORCID https://orcid.org/0000-0002-6248-2549
Ana María García HernandezDepartment of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is essential to evaluate both the patient's prior conditions and the severity of the current clinical presentation when deciding on BTZ toxicity management. It seems prudent to consider the permanent discontinuation of the drug in patients who have experienced at least grade 3 intestinal neuropathy and have structural abnormalities or other risk factors for intestinal perforation.

Indexed as

BortezomibIntestinal perforationIntestinal Pseudo‐obstructionmultiple myelomaperipheral neuropathies

Identifiers

PMID40171013
PMCPMC11959410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.